

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
November 20, 2009**

**ORDER GRANTING CONFIDENTIAL TREATMENT
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**Rexahn Pharmaceuticals, Inc.
File No. 001-34079- CF#23825**

Rexahn Pharmaceuticals, Inc. submitted an application under Rule 24b-2 requesting confidential treatment for information it excluded from the Exhibits to a Form 8-K filed on June 30, 2009, as modified by reduced redactions in the refiled Exhibits to a Form 8-K filed on September 21, 2009.

Based on representations by Rexahn Pharmaceuticals, Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibit will not be released to the public for the time period specified:

Exhibit 10.1 through June 30, 2012

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Jeffrey P. Riedler
Assistant Director